Roxithromycin dosage for children

Roxithromycin is a very common drug in life, and it can be used at any age, including children. However, if children use it, it is best to use it under the guidance of a doctor. If children take it, the dosage is generally taken twice a day, and the best amount for each dose is 2.5-5.0 mg/kg. It can be taken before or after meals.

Roxithromycin dosage for children: 2.5-5.0 mg/kg per day. Take in 2 doses. When this product is used in combination with theophylline or carbamazepine, the dosage does not need to be adjusted. There is cross-resistance between this product and erythromycin. Take 1 hour before or 4 hours after meals. Taking the drug after eating will reduce drug absorption because roxithromycin is a fat-soluble drug. It should be mixed with boiled water or taken with water. It should not be taken with tea or other beverages.

Precautions when taking roxithromycin

1. Cross-allergy: When a patient is allergic to one macrolide drug, he may also be allergic to other macrolide drugs.

2. Use with caution: (1) Patients with impaired liver function; (2) Pregnant or lactating women.

3. When taking the drug for a long time, attention should be paid to monitoring liver function; when roxithromycin is used together with theophylline, theophylline blood concentration should be monitored.

Adverse reactions of roxithromycin

The adverse reactions of roxithromycin are mild and the incidence is low (the overall incidence is about 4%).

1. Gastrointestinal symptoms such as abdominal pain, diarrhea, nausea, and vomiting are more common, but the incidence is significantly lower than that of erythromycin.

2. Occasionally, mild allergic reactions such as rash, urticaria, itching, drug fever, etc. may occur.

3. A small number of patients may occasionally experience abnormal liver function after taking the medicine.

4. A small number of patients occasionally experience symptoms such as headache and dizziness after taking the medicine.

Roxithromycin is a new generation of macrolide antibiotics and a semi-synthetic 14-membered macrolide drug. Its mechanism of action is the same as that of erythromycin, which is mainly to bind to the bacterial 50S ribosomal subunit, inhibit the synthesis of bacterial proteins by blocking transpeptidation and mRNA translocation, thereby exerting an antibacterial effect. Its characteristic is that it can quickly enter macrophages, pneumocytes, alveoli, and polymorphonuclear leukocytes. The antibacterial spectrum of roxithromycin is similar to that of erythromycin. Its in vitro antibacterial effect is similar to that of erythromycin, and its in vivo antibacterial effect is 1 to 4 times stronger than that of erythromycin.

Roxithromycin is slightly less effective than erythromycin against Gram-positive bacteria, but more effective than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. Roxithromycin has strong antibacterial activity against Staphylococcus aureus (except MRSA), Streptococcus (including A, B, C streptococci and Streptococcus pneumoniae, but excluding G type and enterococci), Corynebacterium, Listeria, Moraxella catarrhalis (catarrhal coccus), Legionella, etc.; it also has certain effects on anaerobic bacteria such as oral Bacteroides, black-producing Bacteroides, Peptococcus, Peptostreptococcus, Propionibacterium acnes, as well as Toxoplasma gondii, Chlamydia, Mycoplasma, Ureaplasma urealyticum, Treponema pallidum, etc.; it has weaker effects on Helicobacter, gonococcus, meningococcus, Bordetella pertussis, etc. Roxithromycin can inhibit most Gram-positive bacteria, and its antibacterial activity against common pathogens of respiratory tract and skin infections, such as Staphylococcus aureus, Staphylococcus epidermidis, Pneumococcus, Streptococcus pyogenes, Haemophilus influenzae, Mycoplasma pneumoniae and Legionella, is similar to that of erythromycin. It is effective against urogenital tract infections caused by Chlamydia trachomatis and Ureaplasma urealyticum, and against Treponema pallidum.